Vivos (RDGL) Cyclically Adjusted PB Ratio: (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vivos Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Vivos  (OTCPK:RDGL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vivos Cyclically Adjusted PB Ratio Related Terms


Vivos Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Vivos's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivos Cyclically Adjusted PB Ratio Chart

Vivos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vivos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RDGL vs ARAY, FOFA, TELA: Cyclically Adjusted PB Ratio Comparison

For the Medical Devices subindustry, Vivos's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivos Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vivos's Cyclically Adjusted PB Ratio falls into.



Vivos Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vivos's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Vivos's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.006/330.2130*330.2130
=0.006

Current CPI (Mar. 2026) = 330.2130.

Vivos Quarterly Data

Book Value per Share CPI Adj_Book
201606 -9.118 241.018 -12.492
201609 -8.777 241.428 -12.005
201612 -0.762 241.432 -1.042
201703 -2.849 243.801 -3.859
201706 -2.417 244.955 -3.258
201709 -0.531 246.819 -0.710
201712 -0.519 246.524 -0.695
201803 -0.565 249.554 -0.748
201806 -0.725 251.989 -0.950
201809 -0.388 252.439 -0.508
201812 -0.006 251.233 -0.008
201903 -0.006 254.202 -0.008
201906 -0.007 256.143 -0.009
201909 -0.007 256.759 -0.009
201912 -0.008 256.974 -0.010
202003 -0.007 258.115 -0.009
202006 -0.003 257.797 -0.004
202009 -0.004 260.280 -0.005
202012 0.000 260.474 0.000
202103 0.006 264.877 0.007
202106 0.005 271.696 0.006
202109 0.004 274.310 0.005
202112 0.004 278.802 0.005
202203 0.004 287.504 0.005
202206 0.003 296.311 0.003
202209 0.005 296.808 0.006
202212 0.005 296.797 0.006
202303 0.004 301.836 0.004
202306 0.005 305.109 0.005
202309 0.004 307.789 0.004
202312 0.004 306.746 0.004
202403 0.003 312.332 0.003
202406 0.004 314.175 0.004
202409 0.003 315.301 0.003
202412 0.005 315.605 0.005
202503 0.007 319.799 0.007
202506 0.006 322.561 0.006
202509 0.005 324.800 0.005
202512 0.004 324.054 0.004
202603 0.006 330.213 0.006

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vivos Business Description

Address 1030 N Center Parkway, Kennewick, WA, USA, 99352
Vivos Inc is a radiation oncology medical device company engaged in the development of its yttrium-90 (Y-90) based precision radionuclide therapy devices. Its portfolio includes RadioGel Precision Radionuclide Therapy (Human Division) for treating solid tumors and positive surgical margins in humans and IsoPet (Animal Division) for treating solid tumors in animals. Vivos also sells PLGA-g-PEG polymers and PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents. The company currently mainly operates in the United States.